TOKYOMEDIJAPAN MEDICAL REFERENCE
⌕ Search databaseOfficial source · PMDA / MHLW
Rx · Reference only · no online purchase

Rinvoq (Upadacitinib)

Rinvoq / Upadacitinib. Used for selected rheumatoid arthritis, atopic dermatitis and inflammatory bowel disease, depending on formulation.

PMDAproduct-level source2026-08label updated2026-10-05site verified
リンヴォック錠7.5mg/15mg/30mg/45mg・内用液0.1% · 7.5 mg / 15 mg
Japanese product photo · 7.5 mg / 15 mg · アッヴィ / 共同通信PRワイヤー
Main useUsed for selected rheumatoid arthritis, atopic dermatitis and inflammatory bowel disease, depending on formulation.A brief overview of Japanese approved uses. Check the PMDA label below for product-specific conditions.
Japan product name
リンヴォック錠7.5mg/15mg/30mg/45mg・内用液0.1%
Brand
Rinvoq
Generic name
Upadacitinib
Japanese generic name
ウパダシチニブ
Chinese name
乌帕替尼
Marketing authorization holder
アッヴィ合同会社
Strengths
7.5 mg / 15 mg / 30 mg / 45 mg; oral solution 0.1%
Dosage form
tablet / oral solution
Therapeutic area
Immunology
Regulatory status
Rx
Label updated
2026-08
TOKYO MEDI verified
2026-10-05
MEDICINE REFERENCE

Detailed product reference

Summaries refer to the listed Japanese product. Eligibility, adjustments and full risks depend on its label and strength; a clinician determines individual treatment.

01

Product overview

Rinvoq is an oral JAK inhibitor with multiple tablet strengths and a Japanese oral-solution formulation.

Read source section ↗
02

Mechanism of action

Reversibly inhibits JAK-mediated cytokine signaling and STAT activation.

Read source section ↗
03

Japanese indications & eligibility

Uses include selected arthritis, axial disease, GCA, dermatitis and IBD; pediatric JIA has formulation-specific dosing.

Read source section ↗
04

Administration & dose differences

Adult doses vary by indication. IBD uses 45 mg induction then 15/30 mg maintenance; pediatric solution schedules differ.

Read source section ↗
05

Adverse effects & key risks

Important risks include serious infections, cytopenias, liver injury, thrombosis, cardiovascular events and malignancy.

Read source section ↗
06

Contraindications & special populations

Contraindicated with specified serious infection, TB, severe hepatic/cell-count abnormalities and pregnancy.

Read source section ↗
07

Drug interactions

Review strong CYP3A modifiers, other JAK/biologic/immunosuppressive agents and live vaccines.

Read source section ↗
08

Assessment & monitoring

Screen for TB/infection; monitor blood counts, liver function, lipids and clinical risk.

Read source section ↗
09

Storage & handling

Store by formulation; opened solution is kept upright in the dark and used within 60 days.

Read source section ↗
10

Sources & verification

Product checked ·

Official source

These links go directly to PMDA records for this Japanese product. Professional and patient-facing sources are separated.